NCT02192099: A reported trial by Naurex, Inc, an affiliate of Allergan plc
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02192099 |
|---|---|
| Title | Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Sept. 8, 2014 |
| Completion date | Nov. 8, 2018 |
| Required reporting date | Nov. 8, 2019, midnight |
| Actual reporting date | Nov. 8, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |